|
Team
The Company has been started in April 2005
together with the Fox Chase Cancer Center in Philadelphia by a scientific
and business team that has worked on the discovery and development of novel
cancer treatments in various biotech and pharma companies in their past.
NexusPharma is largely following a "virtual development company"
concept, building on a network of scientific experts and advisors in cancer
research and drug development to advance its first-in-class drug candidates
into clinical development:
Research: Research: The team is lead by Lutz Weber (President) and Steven Per (COO) together with Vladimir Khazak (Director Biology, NexusPharma), supported by Erica Golemis and Michael F. Ochs (FCCC, Philadelphia), Channing J. Der and Sharon Campbell (UNC, Chapel Hill), Fuyuhiko Tamanoi (UCLA, Los Angeles), and David Tuveson (UPenn, Philadelphia).
|